Phase 1 CARDINAL trial evaluating TERN-701 in 2L+ CML patients remains ongoing, with interim data from initial cohorts anticipated in second half of 2024 FOSTER CITY, Calif., April 29, 2024 (GLOBE ...
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for ...
Patients who achieved a major molecular response (MMR; BCR-ABL1 ≤0.1%) within 3 months had a 4-year progression-free survival (PFS) rate of about 80%, whereas those who did not meet that landmark ...
Expert Rev Anticancer Ther. 2008;8(9):1387-1398. Expert Rev Anticancer Ther. 2008;8(9):1387-1398. © 2008 Expert Reviews Ltd. No writing assistance was utilized in ...
ROCKVILLE, Md. and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Ascentage Pharma (6855 HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results